Because each patient's needs are unique, the Spectra Optia system enables you to customize the procedure based on each patient's specific characteristics.
1Tormey CA, et al., "Improved plasma removal efficiency for therapeutic plasma exchange using a new apheresis platform." Transfusion 2010; 50 (2): 471-477.
1/.87 = 1.15
Anticoagulant volume = 1,000 mL/9 (inlet:AC ratio of 10 = 9 parts blood to 1 part AC) = 111 mL
Spectra Optia system: 100% − 87% = 13% of 111 mL = 14.4 mL AC/L processed
Assumptions: AC ratio of 10
NOTE: An AC infusion rate of 0.8 to 1.2 mL/min/L TBV was used during the clinical studies; however, it was not used directly in this calculation.
**Under normal operating conditions, the ECV will not exceed the typical ECV value. Under certain infrequent alarm conditions, such as during reservoir recovery after a reservoir alarm, the ECV may momentarily increase to the maximum ECV value.
This procedure allows you to process patients' plasma through columns, filters and secondary processing systems,1 with features that help advance TPE to the next level of patient care.
1Secondary plasma devices may be used with flow rates from 10 mL/min to 100 mL/min on the Spectra Optia system.
2Check secondary plasma device specifications for requirements.
3Tormey CA, et al., "Improved plasma removal efficiency for therapeutic plasma exchange using a new apheresis platform." Transfusion 2010; 50 (2): 471–477.
By giving you the ability to switch to single-needle access at any time during a procedure, we help you provide exceptional patient care. Plus, you can achieve a level of performance consistent with your dual-needle access procedures.
Provides the flexibility to perform multiple types of RBCX procedures, each tailored to your patient's needs to further help you advance care.
The MNC collection protocol brings efficiency, purity and consistency to collections—ultimately benefiting patients, clinicians and laboratory processes.
By using the Spectra Optia system's automated interface management (AIM) system and the COBE® Spectra Apheresis System's continuous-flow method of mononuclear cell (MNC) collection, the CMNC protocol provides operators with an automated, yet familiar and flexible, method for collecting MNCs, including monocytes, lymphocytes, CD34+ cells and dendritic cells.
Designed to give you both choice and flexibility, the Spectra Optia system helps you optimize each PMN collection procedure.
**Clinical validation data on file.
†Under normal operating conditions, the ECV will not exceed the typical ECV value. Under certain infrequent alarm conditions, such as during reservoir recovery after a reservoir alarm, the ECV may momentarily increase to the maximum ECV value.
Whether you need to perform a WBC or platelet depletion procedure, the advanced Spectra Optia system is designed to provide you choice and precision.
Through helpful on-screen guidance and a single-bag approach, the Spectra Optia system simplifies BMP procedures.
**Data on file.
Possible patient reactions
Reactions to transfused blood products can include1
Restricted to prescription use only
1AABB (ed.), et al., Circular of Information for the Use of Human Blood and Blood Components. 2006, tenth edition, Council of Europe Publishing, Seattle, WA.
2American Society for Apheresis, "Guidelines for Documentation of Therapeutic Apheresis Procedures in the Medical Record by Apheresis Physicians." Journal of Clinical Apheresis 2007; 22 (3): 183.
Products available in select markets.